Method for treating bladder cancer

• US 9,839,621 B2
• Filed: 02/03/2017
• Issued: 12/12/2017
• Est. Priority Date: 07/26/2012
• Status: Active Grant

• Current Assignee: The William M. Yarbrough Foundation
• Original Assignee: The William M. Yarbrough Foundation
• Inventors: Silver, Michael E.
• Primary Examiner(s): Henley, III, Raymond J
• Application Number:
  US15/423,869
• Publication Number:
  US 20170143659A1
• Time in Patent Office: 312 Days
• Field of Search: 514562
• CPC Class Codes: A61K 31/16 Amides, e.g. hydroxamic acids
• CPC Class Codes: A61K 31/195 having an amino group
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 31/26 Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

A method for treating bladder cancer including the steps of administering an isothiocyanate functional surfactant to an area affected by bladder cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.

Claims

1. A method for treating bladder cancer, comprising the step(s) of:

administering a surfactant or a pharmaceutically acceptable salt thereof to an area affected by bladder cancer, wherein the protonated form of the surfactant is represented by the following chemical structure;

4. The method for treating bladder cancer, according to claim 1, further comprising the step of administering an additional surfactant, wherein the additional surfactant is selected from at least one of the group comprising a non-ionic surfactant, an anionic surfactant, a cationic surfactant, a zwitterionic surfactant, and combinations thereof.

5. The method for treating bladder cancer, according to claim 1, wherein the bladder cancer is selected from one of the groups comprising urothelial carcinoma, transitional cell carcinoma, papillary carcinomas, flat carcinoma, squamous cell carcinoma, adenocarcinoma, small cell carcinoma, and sarcoma.

2. A method for treating bladder cancer, comprising the step(s) of:

administering a surfactant or a pharmaceutically acceptable salt thereof to an area affected by bladder cancer, wherein the protonated form of the surfactant is represented by the following chemical structure;

6. The method for treating bladder cancer, according to claim 2, further comprising the step of administering an additional surfactant, wherein the additional surfactant is selected from at least one of the group comprising a non-ionic surfactant, an anionic surfactant, a cationic surfactant, a zwitterionic surfactant, and combinations thereof.

7. The method for treating bladder cancer, according to claim 2, wherein the bladder cancer is selected from one of the groups comprising urothelial carcinoma, transitional cell carcinoma, papillary carcinomas, flat carcinoma, squamous cell carcinoma, adenocarcinoma, small cell carcinoma, and sarcoma.

3. A method for treating bladder cancer, comprising the step(s) of:

administering a surfactant or a pharmaceutically acceptable salt thereof to an area affected by bladder cancer, wherein the protonated form of the surfactant is represented by the following chemical structure;

8. The method for treating bladder cancer, according to claim 3, further comprising the step of administering an additional surfactant, wherein the additional surfactant is selected from at least one of the group comprising a non-ionic surfactant, an anionic surfactant, a cationic surfactant, a zwitterionic surfactant, and combinations thereof.

9. The method for treating bladder cancer, according to claim 3, wherein the bladder cancer is selected from one of the groups comprising urothelial carcinoma, transitional cell carcinoma, papillary carcinomas, flat carcinoma, squamous cell carcinoma, adenocarcinoma, small cell carcinoma, and sarcoma.